"DaxibotulinumtoxinA in the treatment of glabellar lines: Results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2).'
DaxibotulinumtoxinA for injection is a novel botulinum toxin type A formulation in clinical development. A phase 2 dose-ranging study identified an optimal dose and demonstrated efficacy with a median duration of 24 weeks. In two phase 3 multicenter, randomized, double-blind, placebo-controlled studies (SAKURA 1, SAKURA 2), subjects with moderate or severe glabellar lines at maximum frown were randomly assigned to receive placebo or 40U daxibotulinumtoxinA for injection. Glabellar lines were evaluated at least every 4 weeks for ≥ 24 weeks until severity returned to baseline (≤ 36 weeks). Overall, 609 subjects enrolled (405 daxibotulinumtoxinA, 204 placebo). DaxibotulinumtoxinA was significantly more effective than placebo in achieving the primary efficacy outcome (≥ 2-point improvement in glabellar line severity at maximum frown at week 4 according to both investigator and subject ratings) - 73.6% vs. 0.0% (SAKURA 1), 74.0% vs. 1.0% (SAKURA 2) (both p<0.0001). Composite investigator and subject ratings of maximum frown after daxibotulinumtoxinA treatment showed none or mild glabellar line severity was maintained for a median of 24.0 weeks (SAKURA 1) and 23.9 weeks (SAKURA 2) and glabellar line severity did not return to baseline levels for a median of 27.7 and 26.0 weeks. DaxibotulinumtoxinA was generally well tolerated, the most common adverse events related to daxibotulinumtoxinA treatment being headache (7.0% [SAKURA 1], 5.9% [SAKURA 2]), and injection site pain (5.0%, 2.4%). Results from both studies were highly consistent. DaxibotulinumtoxinA for injection may offer a prolonged duration of response (median ≥ 24 weeks) and is generally well tolerated.